{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:21Z","timestamp":1793761041377,"version":"4.6.1"},"reference-count":142,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Antibody-drug conjugates (ADCs) have emerged as a major therapeutic advance in ovarian cancer, particularly when platinum-based chemotherapy is not a treatment option. By selectively delivering potent cytotoxic payloads to tumor cells, ADCs such as mirvetuximab soravtansine (MIRV), targeting FR\u03b1, and trastuzumab deruxtecan (T-DXd), targeting HER2, have demonstrated clinically meaningful activity in selected populations. However, resistance to ADCs inevitably develops through diverse mechanisms, including payload resistance and target antigen downregulation. Continued translational research is therefore essential to identify predictive biomarkers and to optimize novel combination strategies. Beyond ADCs, other systemic approaches have demonstrated survival improvements in PROC even in biomarker-unselected populations, including the addition of the glucocorticoid receptor antagonist relacorilant to nab-paclitaxel and immune\u2013chemotherapy combinations such as pembrolizumab plus paclitaxel with or without bevacizumab. Future directions aim to prioritize synergistic combinations to overcome resistance. This includes pairing ADCs with replication stress inhibitors like ATR inhibitors and WEE1 inhibitors or integrating them with next-generation immuno-oncology platforms such as bispecifics, T-cell engagers, and cancer vaccines, as well as the integration of dynamic biomarkers and quantitative tools to define optimal treatment sequencing and improve patient outcomes in this challenging disease setting.<\/jats:p>","DOI":"10.1177\/17588359261480350","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:34:43Z","timestamp":1787765683000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-7425","authenticated-orcid":false,"given":"Mariana Macambira","family":"Noronha","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Universidade Federal do Cear\u00e1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Felipe","family":"Costa de Almeida","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbert Oliveira","family":"Costa Filho","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Universidade Federal do Cear\u00e1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Venegas","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Carvalho","family":"Gouveia","sequence":"additional","affiliation":[{"name":"Yale University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-034X","authenticated-orcid":false,"given":"Ana C","family":"Veneziani","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.9495"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70123-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100009"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0197"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00819-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31774-X"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/11795549231187264"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00140-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101978"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00783-w"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03448-3"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9738-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0991"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.11.010"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00021-X"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5506"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5622"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00725-0"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30604-6"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1791"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02975-x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115222"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/his.15170"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-026-04398-1"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2026.37.e65"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-4702"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5554"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.085"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70417"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5514"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010098"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45974-w"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100156"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105300"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5515"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3033"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3042"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.650"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5625"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5580"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.783"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT124"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.05.038"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.815"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5517"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3023"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.04.507"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5508"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.011"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005401"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.017"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.020"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.06.016"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.12.017"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(21)00771-X"},{"key":"e_1_3_3_65_2","doi-asserted-by":"crossref","unstructured":"Li L Wu Y Li Q et al. EP323\/#463 Efficacy and safety of mirvetuximab soravtansine in Chinese patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from IMGN853\u2013301 (Soraya China) study. In: ePoster Viewing. BMJ Publishing Group Ltd pp. A210.2\u2013A210.","DOI":"10.1136\/ijgc-2023-IGCS.385"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-ESGO.543"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.03.100"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.782"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5557"},{"key":"e_1_3_3_71_2","doi-asserted-by":"crossref","unstructured":"Gershenson D Redondo A Rouge TDLM et al. PT003\/#255 Clinical outcomes with trastuzumab emtansine or ipatasertib plus paclitaxel for persistent\/recurrent rare epithelial ovarian carcinomas: ENGOT-GYN2\/GOG-3051\/BOUQUET phase 2 biomarker-directed study. In: Short Oral Abstracts (Regular Submission). BMJ Publishing Group Ltd pp. A24\u2013A25.","DOI":"10.1136\/ijgc-2024-IGCS.26"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3128"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003927"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0693"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5551"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.09.023"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy023"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3965"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.05.039"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(22)01541-4"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.975"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5551"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3757"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.776"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.03.061"},{"key":"e_1_3_3_86_2","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/j.annonc.2024.08.777","article-title":"715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang D","year":"2024","unstructured":"Wang D, Wang K, An R, et al. 715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. Ann Oncol 2024; 35: S548. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.777","journal-title":"Ann Oncol"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.09.012"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105206"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5550"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.3013"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252211927"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.001"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-6880"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5627"},{"issue":"16","key":"e_1_3_3_95_2","first-page":"TPS5641","article-title":"RAINFOL-04 (ENGOT-OV96\/GOG-3134): A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) plus standard of care (SOC) vs SOC as maintenance treatment after second-line platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer","volume":"44","author":"Van Gorp T","year":"2026","unstructured":"Van Gorp T, Antill YC, Hasegawa K, et al. RAINFOL-04 (ENGOT-OV96\/GOG-3134): A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) plus standard of care (SOC) vs SOC as maintenance treatment after second-line platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer. J Clin Oncol 2026; 44(16_suppl): TPS5641. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.TPS5641","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.101596"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS5644"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2023.2218643"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1414"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgac084"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3002"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS574"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS5637"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5570"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2981"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12316"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.002"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1039\/D5CB00096C"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35205"},{"key":"e_1_3_3_110_2","doi-asserted-by":"crossref","unstructured":"Oaknin A McKean W van Dongen M et al. Mocertatug rezetecan (GSK5733584) a B7-H4-targeted antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study. Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2026.02.027 (2026; 208(Suppl): S454\u2013S455.","DOI":"10.1016\/j.ygyno.2026.02.027"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102906"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0862"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3546"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-PS13-09"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-024-10278-2"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00476"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0108-9"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0696"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13761"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101126"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172156"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9940-z"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0900-z"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3127"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0403"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1610"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00829-5"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.12.036"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103067"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0647"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1557"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.03.023"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.5594"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.015"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5591"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.049"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01040-2"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02567-6"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105200"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1770"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261480350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261480350","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261480350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:37:05Z","timestamp":1788244625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261480350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":142,"alternative-id":["10.1177\/17588359261480350"],"URL":"https:\/\/doi.org\/10.1177\/17588359261480350","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17588359261480350"}}